PRMT5:MEP50 Are Mediators of Treatment-Induced Neuroendocrine Differentiation in Prostate Cancer. Nam HS, Asberry AM, Deng X, Liu S, et al. Prostate 2025 Jul 17. doi: 10.1002/pros.70006.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nam HS, Asberry AM, Deng X, Liu S, et al. PRMT5:MEP50 Are Mediators of Treatment-Induced Neuroendocrine Differentiation in Prostate Cancer. Prostate 2025 Jul 17. doi: 10.1002/pros.70006.
PMID: 40677010